Protagonist Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
PTGX Nasdaq 2830 www.protagonist-inc.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Protagonist Therapeutics, Inc.

Protagonist Therapeutics (PTGX) Stock Looks Priced At A Premium As Its 7x Three Year Run Continues - Nov 6th, 2026 10:15 am
Earnings Beat Might Change The Case For Investing In Protagonist Therapeutics Stock - Nov 6th, 2026 5:17 am
Protagonist Therapeutics (PTGX) Swung To Profit, Is It A Bargain Or Fully Priced? - Nov 6th, 2026 4:13 am
Protagonist Therapeutics (PTGX) Q3 Earnings and Revenues Surpass Estimates - Nov 5th, 2026 2:45 pm
Protagonist Therapeutics: Q3 Earnings Snapshot - Nov 5th, 2026 2:22 pm
Protagonist Reports Third Quarter 2026 Financial Results and Provides Corporate Update - Nov 5th, 2026 2:05 pm
Niagen Bioscience (NAGE) Reports Q3 Loss, Lags Revenue Estimates - Nov 4th, 2026 4:45 pm
Protagonist Therapeutics (PTGX) to Report Q3 Results: Wall Street Expects Earnings Growth - Oct 29th, 2026 7:00 am
Wall Street Analysts See a 25.34% Upside in Protagonist Therapeutics (PTGX): Can the Stock Really Move This High? - Oct 28th, 2026 6:55 am
Protagonist Therapeutics to Participate in Four Investment Bank Conferences in November 2026 - Oct 27th, 2026 5:00 am
J&J Stock Reclaims 50-Day SMA: Is it Time to Buy, Sell or Hold? - Oct 23rd, 2026 6:37 am
A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on Monday - Oct 20th, 2026 6:59 am
Protagonist Therapeutics (PTGX) Upgraded to Strong Buy: Here's What You Should Know - Oct 15th, 2026 9:00 am
Psoriatic Arthritis Market Landscape: 6 Key Late-Stage Drugs Set to Drive Future Growth | DelveInsight - Sep 21st, 2026 11:00 am
J&J Up 18% in Three Months: Buy, Sell or Hold the Stock? - Sep 18th, 2026 7:05 am
Protagonist Therapeutics Announces $300 Million Share Repurchase Program - Sep 8th, 2026 2:05 pm
Protagonist (PTGX) Swings To A Profit As Two Drugs Near Blockbuster Status - Sep 6th, 2026 6:55 am
MIMRYLO Approval Triggered $275M Payments for Protagonist (PTGX). Are Royalties the Better Commercial Model? - Sep 4th, 2026 10:14 am